Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
NRSN compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name
NRSN
NeuroSense Therapeutics Ltd.
Change
Mkt cap
Revenue
Revenue
LLY
ELI Lilly & Co
Change
Mkt cap
Revenue
Revenue
vs
Compare
NRSN
NeuroSense Therapeutics Ltd.
vs
LLY
ELI Lilly & Co
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Earnings history
Desk
News
Calendar
Saved
Search
Earnings history
last 4 reports each · paired by recency
Method
›
NRSN
No earnings history for NRSN.
LLY
3 of 4
at or beyond implied
Report
implied
realized
× implied
Q3 FY26
±5.1%
▲
+6.63%
×1.29
Q2 FY26
±6.2%
▲
+4.86%
×0.79
Q1 FY26
±5.3%
▲
+9.80%
×1.85
Feb 4 '26
±6.1%
▲
+10.33%
×1.69
= implied
NRSN realized, solid
LLY realized, hatched
One scale, both sides: full bar = 11%
× = |realized| ÷ implied
Source: market data
NRSN
NeuroSense Therapeutics Ltd.
Change
1.33
· pre 1.38
· delayed
Mkt cap
$1.8M
Revenue
—
Revenue
—
LLY
ELI Lilly & Co
Change
1,371.32
· pre 1,363.77
· delayed
Pre-market
Nov 5 '26
delayed
Mkt cap
$1.2T
Revenue
$24.4B
Q3 FY26
Revenue
$65.2B
FY25
vs
Compare
Pre-market
Nov 5 '26
delayed
NRSN
NeuroSense Therapeutics Ltd.
vs
LLY
ELI Lilly & Co
1.33
pre 1.38
delayed
Price
1,371.32
pre 1,363.77
delayed
$1.8M
Mkt cap
$1.2T
—
Revenue
$24.4B
Q3 FY26
—
Revenue
$65.2B
FY25
Change
Change
NRSN
1.33
vs
LLY
1,371.32
Pre-market
Nov 5 '26
delayed